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Abstract 
 
Currently the literature on the risk of breast cancer, comparing MtF patients 
versus cisgender women, does not show a greater risk for MtF patients.  MtF patients are 
not at a greater risk to develop breast cancer than ciswomen.  While the most common 
type of breast cancer in ciswomen is seen in the epithelial component (12% incidence) of 
the mammary tissue, herein this specific population, there are case reports (3) of stromal 
lesions that reflect an increase in the stromal versus epithelial (20 cases reported) ratio of 
breast malignancies(3:20).  The various variables that affect transwomen, like barriers to 
health or lack of proper education within in the medical community are addressed, in 
order to conceptualize the current data. The increased ratio of stromal to epithelial 
malignancies in MtF transgender individuals found in current literature could be 
attributed to the small sample size or truly a potential health hazard. 
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The Increased Ratio of Stromal to Epithelial Malignancies in MtF Patients 
Introduction 
The intake of estrogen by a Male-to-Female (MtF) patient is to ultimately drive 
breast development and cease prominent male traits, such as facial hair or muscle tone.  
The connection between long-term exposure to estrogen and the increased risk of 
neoplasia in the breast in MtF patients is scantily understood.  Currently the literature on 
the risk of breast cancer, comparing MtF patients versus cisgender women, does not show 
a greater risk for MtF patients.  MtF patients are not at a greater risk to develop breast 
cancer than ciswomen.   
However, these results pertain to epithelial breast cancer, but not to stromal 
lesions, which make up less than 1% of breast cancers in the general population. In in the 
very small sample of breast cancers that have been reported in transwomen, stromal 
cancers make up 14%.  Therefore, we need to understand the cellular and molecular 
mechanism of stromal vs. ductal and other epithelial malignancies in MtF patients, and 
decide if this is an anomaly based on small sample sizes or really a potential health 
concern. 
Background 
In order to conceptualize the distinct developmental path of an MtF patient’s 
breasts resulting in their potential increased risk for neoplastia, we must first establish the 
physiological and anatomical development of breasts in general.  There is no sex-related 
difference in breast development prior to puberty, thus embryonic, fetal, neonatal and 
childhood breast anatomy is similar for all typical individuals.  Parenchymal and stromal 
elements comprise the human breast, with the parenchymal portion forming an epithelial 
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system of branching ducts that will eventually lead to the development of secretory acini, 
or milk-producing glands in the adult female breast with appropriate hormonal 
stimulation.  The stroma or mesenchymal connective tissue contains mainly adipose 
tissue (fat), which will provide the environment in which the parenchyma can grow.  The 
first stages of breast growth during embryogenesis are mostly hormone independent 
(Javed & Lteif, 2013), with the development of breast classified into two main processes: 
formation of a primary mammary bud and development of a rudimentary mammary 
gland.   
The primary buds form into two separate areas of epithelial cells, with the 
surrounding mesenchymal cells differentiating into fibroblasts, vascular smooth muscle 
cells, capillary endothelial cells and adipocytes.  The primary mammary bud vertically 
grows into the mesenchyme, which surrounds the primary bud. Secondary epithelial buds 
develop from the primary, with a narrow stalk and a bulbous end termed the terminal end 
buds.  These epithelial cells grow vertically into a second stromal section, named the 
mammary fat pad (pre-adipocytes at this stage), in a process termed ductal 
morphogenesis.  From the canalization and cleaving of the terminal end buds comes the 
rise of the lactiferous duct, which is the initial duct tree trunk.   There are two layers of 
epithelial cells within the lactiferous ducts. The secretory function is within the layer of 
cells next to the lumen, and the basal layer becomes myoepithelial cells; together they 
form the preliminary epithelial ductal system.   The basic framework of the gland is 
established by the end of the second trimester, with defined tubular structures surrounded 
by dense fibroconnective tissue.  Breast tissue is apparent in both males and females at 
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birth, where the rudimentary gland is established and will grow parallel to normal body 
growth until puberty.   
Compared to fetal breast development, which is considered to be sex- and 
hormone-independent (Javad & Lteif, 2013), pubertal and adult mammary gland 
development is sex-specific and hormone-dependent (Parent et al., 2003).  During 
puberty in the female, there is primarily ductal elongation and side branching triggered 
through recurring estrous cycles (Parent et al., 2003).   In puberty, estrogens are the key 
mitogenic stimulus for DNA synthesis and the increase of bud and duct formation.   
During puberty, the epithelium branches, forming additional bilayered ductal structures 
that consist of an outer basal myoepithelial layer of cells and an inner luminal layer.  The 
luminal cell layer can be further divided into ductal luminal cells, lining the inside of the 
ducts, and alveolar luminal cells, that will secrete milk during (future) lactation. [The 
further development of the alveoli is dependent on another hormone, Progesterone.] At 
the culmination of the pubertal phase, while the underlying changes at the molecular level 
are occurring, extensive tissue remodeling impacts both stromal and parenchymal aspects 
of the breast.  Thus, under the influence of estrogen, there is an increase in fibrous and 
fatty tissue of the stroma followed by ductal elongation and bifurcation of terminal end 
buds (Javed & Lteif, 2013).   
Hormone Receptors 
As with other steroids, estrogen acts via a nuclear steroid receptor, the estrogen 
receptor (ER), which upon activation by estrogen (ligand) forms a homodimer with 
another ER-ligand complex that leads to the activation of the transcription of specific 
genes that contain estrogen response elements.  As there are two known estrogen 
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receptors, ER-𝛼 and ER-𝛽, studies have been performed to determine which is 
responsible for mammary proliferation (Paterni, et al., 2014).  Both estrogen receptors are 
found distributed along breast tissue, and both are known to play a role in breast 
development (Paterni, et al., 2014).  Research on mice tracked the presence of both 
receptors in the female body throughout the key physiological stages that a female 
undergoes: pregnancy, lactation and post lactation, in order to hone in on the specific role 
of each receptor and establish the exact onset of expression for each (Paterni, et al., 
2014).   
According to Briskin and colleagues (2010), the two ERs relatively changed 
depending on the endocrine status of the mammary gland.  During pregnancy, ER-𝛼 
expression was less than 20-percent but during lactation it increased to 45-percent within 
the first week, then to 70-percent by the third week.  Throughout various physiological 
stages depicted, ER-𝛽 was seen to be consistently present in more than half the epithelial 
cells.  During the highly proliferative period of pregnancy, ER-𝛽 was the dominant 
receptor.  During lactation, which is considered a non-proliferative period, both receptors 
were notable to be present but the ratio of ER-𝛽 to ER-𝛼 was reduced (Briskin, 2010).  
The message from this study is that between these receptors, there were no clear 
indications of which is key, 𝛼 or 𝛽, as both are present during each physiological stage.  
In other words, both receptors were seen in the different physiological stages of breast 
development in female mice.  Since there isn’t specific information on the exact pathway 
of cis-females and MtF breast development in humans, it is understood to follow the 
same basic pathways as female breast development in puberty in other mammals. Thus, 
we will consider that both receptors may play a role in both cis-female and MtF human 
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breast development.  However, as this data is purely correlational, it would be better to 
find a loss of function study to determine which of these receptors is actually necessary 
for breast development. For that we go back to mice. 
Most of the information on estrogen receptors has been learned from studies in 
rodents. In a study done by Bocchinfuso et al. (2000), scientists targeted hormone 
receptor genes, and generated mice that were unresponsive to reproductive hormones, 
since their cognate receptors were lacking.  All the mice were viable, but had 
reproductive deformities.  ER-𝛼 is expressed in both the mammary epithelium and 
mammary stroma.  The ER-𝛼 gene was disrupted through the insertion of a neomycin 
resistance gene (neo) into its first coding exon, which caused the elimination of ER- 𝛼.  
In females that were ER-𝛼 -/-, (homozygous for the knock out), mammary gland 
development was equivalent to those of the wild-type (wt) cohort until the pubertal phase, 
from which point no additional development was seen through stereomicroscopy and 
histology. Thus, ER-𝛼 -/-, was shown to not be necessary for initial budding (hormone 
independent), but necessary for hormone dependent ductal elongation, side branching and 
alveologenesis of puberty. In contrast, mice that had ER-𝛽 knocked out (𝛽ERKO) 
demonstrated normal development of the mammary tissue (Couse et al., 1999). Thus, in 
puberty, estrogens are the key mitogenic stimulus and signal via ER- 𝛼, by stimulating 
DNA synthesis and increasing bud formation.  
Similar to the ER- 𝛼 receptor, the progesterone receptor (PR) is expressed in both 
the mammary stroma and mammary epithelium.  Progesterone’s main function is to 
induce proliferation of the endometrium every month during the menstrual cycle in 
preparation for pregnancy, but itis also the key stimulator of mammary epithelial DNA 
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synthesis and alveolar development.  The elimination of ER- in the neo experiment 
(Bocchinfuso et al. 2000) also caused the nearly complete disappearance of the 
progesterone receptor (PR), because its expression is highly controlled by ER-.   
Typically, the presence of growth hormone (GH) induces the increase of estrogen, which 
through binding ER- sets the stage for progesterone action, through the induction of the 
PR (Kraus et al., 1990).  This phase has been coined as “estrogen priming,” which occurs 
in the majority of progesterone target tissues (Shyamala et al., 1990).    
 Progesterone levels were low in the ER-𝛼 knock out (𝛼ERKO) mouse, pituitary 
grafting and hormone replacement (exogenous estrogen doses) were used to determine 
estrogen’s role regarding progesterone levels.  In the presence of estrogen (grafting and 
hormone replacement), progesterone was shown to directly stimulate mammary gland 
development in the 𝛼ERKO out mouse.  Reduction of PR epithelial cells of females 
failed to side branch and form alveoli, which indicated that progesterone receptor 
signaling is necessary for side branching and alveologenesis.  Furthermore, upon the 
exogenous introduction of estrogen and progesterone in 𝛼ERKO mice, ductal and 
alveolar development was seen.  Exogenous progesterone and estrogen in 𝛼ERKO mice 
showed a 20-30% increase of PR mRNA, which could be due to indirect ER-𝛽 effects on 
progesterone.  However, mammary gland development was successful in mice that were 
in PR deficient only in the stromal tissues, indicating that the receptor is necessary in 
epithelial cells but not in the stroma.   
In conclusion, ER- 𝛼 gene disruption leads to reduction in PR production due to 
the failure to induce the PR gen in mammary epithelia, which plays a role in the lack of 
ductal morphogenesis and alveolar development as seen in 𝛼ERKO mice.  Furthermore, 
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the reduced circulating levels of progesterone contribute to the deficient mammogenic 
signaling seen in the ER-𝛼 knock out mice.  Additionally, because mice that had 𝛽ERKO 
demonstrated normal development of the mammary tissue, this fails to support the earlier 
speculation about the importance of ER-𝛽 in breast development that led to the 
hypothesis that the ER-𝛽 role in breast development was necessary.  Thus, the 
experiments discussed here together demonstrate that the ER- 𝛽 and estrogen signaling 
pathway is not needed for breast development, but also reinforce that ER- 𝛼 /E2 signaling 
is required directly for the morphogenesis of breast ducts, and indirectly through PR for 
the morphogenesis of breast side branching and alveologenesis.  
Mammary Epithelial Tissue 
Types and frequency of epithelial breast cancers (carcinomas). The mammary gland 
continues to undergo molecular changes throughout life that can lead to atypical growth.  
The most common breast cancers, carcinomas, arises from abnormal and proliferative 
behavior of cells (neoplasm) within the epithelia that will eventually extend into the 
periductal stroma or connective tissues (Modern surgical pathology CH 19).  The exact 
etiology of breast cancer is one that continues to require research, but estrogen is 
considered to be a key growth hormone for both normal and neoplastic breast epithelium 
(Russo J. & Russo I., 2004).  The exact mechanism by which estrogen promotes tumor 
proliferation is not fully understood, but the fact that 99% of epithelial breast cancer 
occurs in women (Allred et al., 2004) and that 92% of breast cancers express a type of 
estrogen receptor (ER) mRNA (Briskin, 2010), permit scientists to continue to look at 
estrogen’s role in breast cancer development.   
  14
In their lifetime, one in eight (12%) cisgender women will be diagnosed with a 
form of epithelial breast cancer (National Breast Cancer foundation), making it the most 
common form of cancer overall, and the second leading cause of cancer death in women.  
Most breast cancers are epithelial in origin, with the most common derived from the 
terminal duct-lobular unit, the mammary ductal epithelium (Yerushalmi et al, 2009).   
Approximately 95% of carcinomas are in the ductal and lobular unit of the mammary 
(Ulster, 2009); 75% of them are invasive ductal carcinomas, and invasive lobular 
carcinoma is the second most common (5% - 15%) (Yerushalmi et al, 2009).  
Furthermore, statistics show that approximately 80% of cancers in the breast are ER-
positive, 65% of those are PR-positive (American Cancer Society, 2019) and, ER- 𝛼 is 
present in approximately 50-60% of breast cancers (Hinck & Silberstein, 2005).  More 
specifically, 40% of ductal carcinomas (most common type of breast cancer) have ER- 𝛼 
expression.  Thus, hormone receptors are major contributors to the field of breast 
oncology and define key steps for diagnosis and prognosis in patients. 
Epithelial breast cancers are typically classified into three subcategories: estrogen 
receptor (ER)/ progesterone receptor (PR) positive, which is considered luminal; human 
epidermal growth factor receptor 2 (HER2) positive, and triple negative breast cancer 
(TNBC), ER/PR/HER2 negative (Hua, 2009).  Luminal cancers can be further divided 
into two categories: Luminal A cancers are considered to have a low proliferation rate 
without the presence of HER2 receptors (Britten et al, 2013); Luminal B cancers, on the 
other hand, have a high proliferation rate and are HER2 positive; these are considered to 
be “HER2 driven cancers” (Sorlie et al, 2001).  Most breast cancers are typically estrogen 
and progesterone receptor positive (Clarke et al, 2003).  Both estrogen and progesterone 
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receptors are of importance when looking at pathological and normal development of the 
breast in ciswomen.   In keeping with the focus of this review, which is breasts 
development and cancer in MtF patients, a closer look into estrogen receptors role in 
breast cancer proliferation and treatment is needed.   
Epithelial Breast Cancer Treatment 
The target in the search for treatment and prevention of developing breast cancer 
altogether is predominantly focused on estrogen and its receptor, ER, due to the fact that 
both are critical players in breast development (Joensuu et al., 2013) Along with ER, the 
two other receptors that are important when it comes to breast cancer are PR and HER2.  
Like ER, PR stimulates gene transcription of mammary epithelial DNA and is key in 
alveolar development (Russo J. & Russo I., 2004).  Both, ER-𝛼 and ER-𝛽 cause 
upregulation of PR, which leads researchers to the deduction, that the combination of 
estrogen along with progesterone in menopausal treatment stimulates breast cancer 
(Russo J. & Russo I., 2004). Without hormone receptor expression, endocrine therapy 
(intake of drugs that inhibit and/or induce hormonal levels) is not an option for treatment, 
since the cells will not be able to take up the hormonal therapy and initiate a signaling 
(Russo J. & Russo I., 2004).  Thus the absence of sex steroid receptors on cancer cells 
results in a higher risk for cancer progression and ultimately death (Allred et al., 2004). 
The receptor that has not yet been covered, HER2, is found to be overexpressed in 
almost 25% of breast cancers (Warfard & Jasani, 2016).  The presence of HER2, dictates 
the use of drugs that target HER2, such as Herceptin (Warfard & Jasani, 2016).  HER2, 
PR, and ER detection are critical in defining the steps towards adequate treatment for 
breast cancer patients, since their presence allows not only the use of endocrine therapy, 
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but may diminish the need for chemotherapy.   For example, triple negative ductal 
carcinoma lack expression of all three receptors and is also considered the most 
aggressive since the progression of such cannot be deterred through the additional use of 
endocrine therapy (Allred et al., 2004).  However, HER2 and PR have been noted to play 
a role in the determination of mortality risk once diagnosed.    
A study by Missmer et al. (2004) looked into the relationship between hormone 
levels and receptor status from examining 322 cases of breast cancer in postmenopausal 
women. Of the 322 cases found during their prospective analysis, 153 were ER and PR-
positive (ER+/PR+) and 39 were ER and PR-negative (ER-/PR-).  Each case was age 
matched to two control subjects that had their blood sample collected on the same month 
and time of day, to compare endogenous hormone levels available in blood plasma.  
Their results demonstrated a strong association between levels of circulating sex 
hormones and the risk of developing ER+/PR+ breast tumors.  Thus, reinforcing the 
focus of scientist on ER and breast cancer links for future prevention and treatment.  
However, conflicting studies throughout time have emerged showing relationships 
between estrogen and breast cancer risks in postmenopausal women using hormone 
replacement therapy (HRT); that could also be contributors to the inability to uncover the 
mechanistic pathway of estrogen in regards to breast cancer risks.    
Hormone Replacement Therapy 
An infamous study done by The Collaborative Group on Hormonal Factors in 
Breast Cancer (1997) included 52,705 women with breast cancer and 108,411 without, 
from a pooled analysis of 51 epidemiological studies from 21 different countries.  Their 
results concluded an increased risk of breast cancer development in current HRT users, 
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with a 2.3% (95% CI, 1.0% - 3.6%) risk increase in each year of usage.  Women that 
used HRT for 5-years or more had a 35% increase risk of breast cancer, compared to 
nonusers.  The increased risk disappeared in HRT users that had stopped using for at 
least, 5- years or more.  It is important to note, The Hormonal Group stated that the 
average year of diagnosis among the 52,705 women with breast cancer was 1985, which 
at the time, HRT consisted of predominantly estrogen alone.  The combinations of both 
estrogen and progestin in HRT began to increase in popularity around the 1990’s, which 
is now the predominant type of HRT used today (Hall & Tressell, 2012).  This study set 
an alarming wave throughout the medical community, but since then have been 
reevaluated and shown to be wrong.   
 Fournier et al. (2008) focused on estrogen and progestin in HRT during 
menopause, in 1,726-breast cancers found in their reanalysis of cohort data of 53,000 
postmenopausal women.  Their results demonstrated a 50% increased risk of breast 
cancer in HRT users that began using closer to menopause, versus nonusers.  This result 
included the first 2-years of HRT usage, but in women that began HT at 3-years or more 
after menopause did not have an increased risk within usage of 2-years or less; however, 
did demonstrate a higher risk for longer usage, almost to that of women that began HT 
closer to menopause.   
Additionally, studies have demonstrated that breast density increases after HRT is 
initiated in postmenopausal women (Greendale et al., 2003).  The Women’s Health 
Initiative (WHI) (2005), investigated the effects of progestin and estrogen versus estrogen 
only HRT, on breast density in a total of 16,608 postmenopausal women.  There was 
approximately a 6% (95% CI, 4.6 – 7.5)  increase of breast density in 75% of the women 
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using estrogen and progestin HRT for one year, compared to only the 0.9% (95% CI, 1.5 
– 0.2) increase in the non-HRT users (placebo group).  The overall consensus in the 
medical community continues to reflect the above studies, that combination HRT 
increases breast density by approximately 75% (even when used for only a short time); 
additionally, through increased breast density that is considered to have 4-6-fold increase 
risks of breast cancer (McTiernan et al., 2005). 
In 2017, Manson et al., performed an in depth analysis of past HRT clinical trials.  
The study included an 18-year follow up, which prior studies lacked, and was published 
in the Journal of the American Medical Association (JAMA), a journal that requires high 
quality statistical modeling.  The study demonstrated that HRT users did not have higher 
mortality rates, specifically of cancer, compared to non-users.  More importantly, the 
study reflects, with analytical data, the current recommendations and beliefs of the 
medical community today; HRT should be an individual decision, based on the vast array 
of effects it has on human physiology.   
Mammary Stromal Tissue 
Hormone receptors on stromal tissue.	In terms of epithelial malignancies, hormone 
receptors are key factors when clinicians are considering prognosis, treatment and 
survival (Conzen, 2008). Current research is heavily focused on finding preventive 
pathways and better treatment avenues for epithelial breast cancers in regards to hormone 
receptors, primarily ER- 𝛼 and PR (Mueller et al., 2002).  However, there is limited data 
on hormone receptors expression in the stroma, which has been established in rodents, to 
play a role in tumorigenesis and tumor growth (Sympson et al., 1995; Barcellos & 
Ravani, 2002).  There are 48 different hormone receptors (Margolis et al., 2005) that are 
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involved in cellular proliferation and apoptosis (through regulation of target transcription 
gene expression).  Knower et al. (2014) set out to identify which receptors were 
expressed in breast stromal tissue.  They compared stromal tissues from normal and ER-
positive cancerous patients to examine normal adipose fibroblast (NAFs) and cancer-
associated fibroblasts (CAFs), respectively.  Fibroblasts have been shown to be key 
mediators in tumor progression (Zamora et al., 2016).  In their analysis, they found that 
the hormone receptors expressed in the cancerous stromal tissue are key players in 
regulation of aromatase.  Aromatase is the main enzyme involved in the final steps of the 
biosynthesis of estrogen, in both males and females (Manna et al., 2016).  The authors 
concluded that the disruption in aromatase regulation contributed to the increase of 
estrogen in ER-positive tumors. 	
Types and Frequency of Stromal Cancers (Sarcomas) 
 Breast malignancies that are non-epithelial, such as sarcomas, comprise less than 
1% of all breast tumors (Ulster, 2009).  Considering the small number of cases that 
appear as non-epithelial cancers in the general population, it is of no surprise that little is 
known of these types of tumors.  Non-epithelial tumors of the breast include primary 
lymphomas, sarcomas, and hematological malignancies (Sullivan et al, 2004), with most 
cases having no known etiology, whereas others are possibly attributable to prior cancer 
therapy, such as radiotherapy (Chugh & Baker, 2004).   
 A retrospective study done in Northern Ireland, conducted over 14-years by 
O’Donnell et al. (2009) reviewed the prognostic outcome of non-epithelial breast cancers 
through the review of patient’s medical records.  Their investigation consisted of data 
from local hospitals, which demonstrated a total of 19 cases of non-epithelial cancers of 
  20
the breast from a total of 3,900 breast cancer cases found.  Lymphomas (0.21%) were the 
main type and Sarcomas (0.13%) being the second type of non-epithelial cancers found 
from all breast cancers found.  At the culmination of the 14-year study, nine patients were 
still alive, but nine others passed away due to their tumors, and another died from non-
breast cancer related issues.  The authors concluded that these types of cancers are rare 
compared to the 95% of epithelium breast cancers found, but that these carry a significant 
mortality rate.   O’Donnell and coworkers encouraged researchers to continue the 
investigation of the outcome and etiology of patients diagnosed with non-epithelial 
malignancies.   
Another retrospective study conducted over the course of four years (1994-1998) 
with a total of 363,801 cases of newly diagnosed breast cancer, found that approximately 
0.4% of the tumors were primarily sarcomas (Young et al, 2004).  A more recent 
investigation by Chirilia et al. (2017) looked into prognostic factors and outcome 
variability in breast sarcomas and malignant phyllodes (a type of non-epithelial tumor).  
The retrospective study was done over a 10-year period (2005-2015), and uncovered 67 
non-epithelial cancers, with 40 of them being breast sarcomas (59.7%) and the rest (27) 
being malignant phyllodes (40.3%).  The authors concluded there were no significant 
differences in outcomes because patients with sarcoma were treated the same as those 
with malignant phyllodes, and resulted in the same overall survival rate.   
In this last study, patients with sarcoma were treated the same as patients with 
malignant phyllodes tumors, although, phyllodes are a specific subtype of non-epithelial 
malignancies.  Primary sarcomas arise from mesenchymal tissues of the breast, with the 
annual incidence rate of 44.8 new cases per 10 million (Wang et al, 2014).  Phyllodes on 
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the other hand, are derived from stromal connective tissue and have epithelial elements, 
while most phyllodes tumors are found to be benign (35-64%) there are cases of low-
grade malignant tumors (borderline) and malignant (Chugh & Baker, 2004).  Some 
scientists have attempted to separate phyllodes from sarcomas (Fields et al, 2008; Adem 
et al, 2004; Bousquet et al, 2007), due to the presence of epithelial elements in phyllodes, 
but this segregation is resisted by others because of the similar clinical and survival 
components of both (Chirilia et al., 2017;Terrier et al, 2000; McGregor et al, 1994).  The 
difficulty in drawing the definitive line between sarcomas and phyllodes is further 
compounded due to the limited amount of research and number of cases available.  For 
now, researchers and clinicians are trying to decide the appropriate course of action when 
it comes to phyllodes and sarcomas.  The basic take home message, however, is that for 
ciswomen, these tumors are exceedingly rare, but have high mortality.   
Stromal Malignancies in MtF Women 
 A recent worldwide literature review done by Joint et al. (2018) identified 20 
cases of epithelial breast cancer in trans women. This demonstrates two notions. First, 
that only a few cases exist, which could be attributed to small population sizes or to lack 
of a representative sampling of data from this population.  Secondly, of the current cases 
of breast cancers in MtF uncovered, the incidence overall is certainly not significantly 
greater when compared to rates in ciswomen (20:260,000; Dykes et al., 2018), and is 
hardly greater when compared to cismen (20:2,670; American Cancer Society, 2019).  
However, of the data we do have, current case reports on stromal lesions of the breast in 
MtF show a drastic difference in ratio of ductal to stromal, compared to that of ciswomen 
(Bryan et al., 2018; Richards et al., 2017; Tongson et al., 2017).   
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 As mentioned, less than 1% of breast cancers are non-epithelial tumors in the 
general population.  However, in the breast cancer literature we have three individual 
case reports of stromal lesions presented in MtF patients. Essentially, in the general 
population, there are 99 cases of epithelial breast cancer and only one of stromal.  Where 
as in the MtF breast cancer literature, we find 20 cases of epithelial breast malignancies 
versus three stromal malignancies (Bryan et al., 2018; Richards et al., 2017; Tongson et 
al., 2017).  This ratio seen in MtF of stromal to epithelial (3:20) malignancies is 
drastically different than the ratio seen in ciswomen (1:99).  In regards to cismen, the 
ratio of ductal versus stromal is harder to define when looking at the available date.  
Similar to ciswomen, various studies (Muir et al., 2003; Buirhafour et al., 2007; Cutuli et 
al., 2010; Aagwar et al., 2014) report that invasive ductal carcinoma is the predominant 
cancer found in males, thus epithelial cancer.  Furthermore, after a literature review of 
English data, Al-Benna et al. (2010) found that 98.5% of sarcomas are found in women, 
while only 1.5% occurred in men.  By calculation, 1.5% of <1% or 0.015% off cancers 
overall should then be sarcomas in males.  
MtF Case Reports on Stromal Malignancies 
Overall, stromal malignancies are an extremely rare entity in the general 
population, but in MtF, these cases reported are a definite signal for further research in 
order to determine if they are anomalies due to limitations on current data and case 
reports, or if they are a cause for concern from the medical community when serving this 
population. 
The first case is by Bryan et al. (2018) is of a 76-year-old MtF patient that 
developed an estrogen receptor positive mammary myofibroblastoma (MFB), a stromal 
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lesion, after receiving estrogen hormone therapy (HT) over 13 months.  It was concluded 
that this was the first reported case of MFB in a transgender patient, after a literature 
review to identify all reported cases of breast neoplasia was conducted.  This type of 
tumor is also called a benign spindle cell lesion with predominant myofibroblastic 
differentiation (Yu et al., 2018).   Specifically, this case is not only unique because of the 
rarity of tumor type and origin but also due to the presence of ER positivity.  ER 
positivity is seldom seen in this tumor type, because it is typically found in older 
postmenopausal ciswomen and older cismen, both of whom have low estrogen levels (Yu 
et al., 2018).    
The second case is of a 38-year-old MtF transgender patient who presented with 
pseudoangiomatous stromal hyperplasia (PASH, a stromal lesion), along with lobular 
hyperplasia (an epithelial lesion).  The patient had been taking estrogen for six months 
when she discovered a lump in her right breast.  In this case, the patient had a history of 
breast cancer in her immediate family, where two of her sisters were diagnosed and one 
passed away from it. Case report did not include type of cancer patient’s family members 
had.  This case study highlights the importance of implementing medical pre-screening 
guidelines, since this specific individual had a higher risk for neoplastic development.  
Similar to the first case, PASH is a rare and benign mesenchymal lesion that is caused by 
proliferation of stromal myofibroblasts (Bowman et al., 2013).  This lesion is extremely 
uncommon in cisgender females, with fewer than 200 cases reported since its discovery 
in 1986 (Jauno et al., 2010), and mostly presented in premenopausal women (Bowman et 
al., 2013).  The etiology and pathogenesis of PASH is unclear, but they are considered to 
be due to hormonal factors, since it mostly occurs in hormonally active women, i.e. 
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premenopausal (Bowman et al., 2012).  Another piece of evidence supporting the 
etiology of PASH being due to estrogen and progesterone levels is the fact that the largest 
masses of PASH were seen in women with the highest levels of hormonal activity 
(Brown et al., 2012).  
The final case by Richards et al. (2017) of a 25-year-old MtF patient that 
presented with benign phyllodes tumor (PT) after taking estrogen intermittently since the 
age of 12.  She began taking estrogen in the form of oral contraceptives from her cousin 
when she was 12, and at age 16 she was prescribed estrogen.  Due to her insurance and 
financial situation she was not able to afford it from her provider, so she purchased from 
acquaintances at other times, thus her estrogen exposure overall is uncertain and 
incompletely documented.  Benign phyllodes tumor (PT) is one of the two main types of 
fibroepithelial lesions, with fibroadenoma being the other.  PT arises from proliferation of 
both stromal and epithelial factors but its neoplastic factor comes from the stroma.  More 
recent studies have revealed that interaction between the stroma and epithelium is lost in 
PT, which can lead to an increase in mitotic activity in the stroma and overall stromal 
proliferation to progress into malignancy (Sapino et al., 2006).  Malignant PT is more 
commonly seen in women of ages 45-49 and benign PT, as is the case with this patient, in 
younger generations.   With regards to hormone receptors, neither malignant nor benign 
PT differ in its overall hormonal expression, however, ER expression was greater in 
benign PT, which are those typically found in hormonally active women.   
Individually, each of these three cases denotes atypical pathological occurrences 
in their own realm, however, combined with the intake of feminizing hormones 
emphasize the need for further research.  All three cases depict rare lesions from 
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unknown etiology but all three types of pathology have been attributed to possible 
connections to hormonal levels in ciswomen.   When taken out of context of the specific 
population it was found in, the literature clearly implies aberrant hormonal levels are 
involved. There are other overlapping similarities between the three tumor types as well.  
PASH and MFB have been regarded as “closely related” due to their morphological and 
immunophenotypical similarities: both being produced from myofibroblasts, developing 
into solid spindle cell masses, and expressing ER and PR.   In terms of clinical findings, 
imaging from mammograms and ultrasounds, practitioners often misdiagnose PASH as 
fibroadenoma, due to the presence of a dense mass during clinical examination, which 
more likely tend to be fibroadenomas (Bezic & Srlbjin, 2018); and as mentioned above, 
fibroadenoma and PT are both a type of fibroepithelial lesions.  Histologically speaking, 
however, PT demonstrates eminent “leaf-like architecture and exaggerated 
intracanalicular stromal growth pattern” whereas fibroadenoma and PASH do not. 
In addition, all three stromal tumor types have two additional intriguing 
similarities that reinforce the contention that each can be due to estrogen levels.  All three 
lesions have been found at a very minute (less than 1%) percentage in men with 
gynecomastia, estrogen-induced pathological breast growth.  More specifically, the 
abnormal hormone levels in the context of gynecomastia are an increase in estrogen or a 
decrease in androgen in the estrogen to androgen ratio.    
The implication of hormones as the culprit is further strengthened by the second 
similarity, the presence of ER and PR in all three-tumor types.  A study on PT used 
evidence from a PASH study by Bowman et al. (2012), which states “that 95% of the 
PASH tumors in our study stained positive for ER and/or PR receptors and a study from 
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Sapino et al. (2006), which declares “the presence of ER-𝛽 within the stromal cells and 
epithelial cells of fibroadenomas and phyllodes tumors,” in order to stress their deduction 
of estrogen as the culprit for the mechanism of pathogenesis.  Finally, a study on MFB 
“found a strong ER/PR nuclear labeling in 70-90% of the neoplastic cells in all cases of 
MFB” (Magro et al., 2000).  The three tumor types individually paint a collective portrait 
where the protagonist is at center stage, estrogen and, in the context of the subpopulation 
that is the topic of this thesis, which further compounds our alarm at these findings.  
Male Breast Cancer in XY Individuals  
Gynecomastia. Gynecomastia is one of the most common breast conditions in males, 60-
90% (Cuhaci et al., 2014) of male infants develop neonatal gynecomastia from exposure 
to high estrogen levels during pregnancy (Cuhaci et al., 2014), and at least 50-55% (M-2) 
of the male population will be affected in their post-natal lifetime.  There is an increase in 
incidence of gynecomastia with age (Sansone et al, 2016), attributed to the decrease in 
testosterone that occurs in aging males (Golan, 2016) due to lower function in both 
testicular and hypothalamic-pituitary axes (Golan, 2015).  The cause of gynecomastia 
remains unclear, but typically, the medical community attributes it to excess endogenous 
estrogen and/or a deficiency in androgens (Sansone et al, 2016).  Although testosterone is 
the dominant sex hormone in males, estrogen is found at low levels in various points of 
development and it aids in spermatogenesis (Hess, 2003).  Low levels of circulating 
estrogen come primarily from the conversion of androgens and testosterones through the 
enzyme aromatase, located in the testes (Hess, 2003) and adipose tissue (Lee, 2013). 
 Olsson et al. (2002) performed a prospective cohort study on 446 men from 1970-
1979, to assess whether there was a correlation between gynecomastia and an increased 
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risk of cancer.   Gynecomastia was confirmed through histological screenings.  Their 
analysis demonstrated a significant increased risk for testicular cancer and squamous cell 
carcinoma of the skin in men with gynecomastia.  Although their findings did not include 
breast cancer (presumably because none was found), it is important to examine further 
the importance of their findings between gynecomastia and testicular cancer. 
 According to recent studies, gynecomastia may be an early symptom of testicular 
cancer (Djaladat et al, 2019; Kolitsas et al, 2011; Dupar et al, 2003).  Dupar et al (2003) 
were the first to report estrogen-caused gynecomastia due to a germ-cell testicular tumor.  
Germ-cell tumors (GCT) comprise 90% of testicular tumors (Olsson, 2016). Some 
secrete estrogen or human chorionic gonadotropin (hCG), which promotes the 
aromatization of estrogen from testosterone in the testes (Kratz et al, 2010).  However, 
Dupar and similar studies may have mistaken correlation for causality between 
gynecomastia and aberrant estrogen levels. There are conflicting studies that demonstrate 
the opposite causal relationship of the Dupar study. In these studies, increased levels of 
estrogen cause the proliferation of testicular malignancy (Bouskine et al, 2008; Pais et al, 
2003; Strohsnitter et al, 2001; Dieckman et al, 2001; Wein et al, 2000; Depue et al, 1983; 
Henderson et al, 1983).  Since increased estrogen causes gynecomastia and increased 
estrogen is correlated with testicular malignancies, it is logical that gynecomastia and an 
increased incidence of testicular cancer will also correlate. The real take home message 
for our purposes is that XY individuals may have estrogen-sensitive neoplasms that 
correlate with increased estrogen levels.   
Klinefelter syndrome. Two in 1000 newborn boys will have Klinefelter Syndrome 
(Bojensen et al., 2003); these individuals are born with at least one more X added to their 
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XY karyotype, typically seen as 47 XXY (Herlihy et al., 2011).  Due to the genetic 
abnormality of the extra X, individuals affected present with testicular dysgenesis, 
sterility, gynecomastia and sometimes forms of psychological disorders (Herlihy et al., 
2011).  Various studies have been performed throughout history to examine the effects of 
this genetic anomaly.  Wang et al. (1975) examined the endocrine profile of 19 patients 
with Klinefelter Syndrome (KS), found low levels of circulating free testosterone, but 
increased levels of luteinizing hormone (LH), follicular stimulating hormone (FSH) and 
estrogen. More importantly, scientist uncovered higher rates of testosterone converted 
into estrogen by peripheral organs.  Another study by Hultborn et al. (1997) examined 93 
cases of male breast cancer and established a 7.5% prevalence rate of Klinefelter 
Syndrome, which authors translated into a 50-fold increase risk for breast cancer in 
patients with Klinefelter Syndrome versus males with the typical XY karyotype.   
Estrogen treatment for prostate cancer. Prostate cancer is sometimes considered to be 
an androgen-dependent malignancy, in which cases the treatment with estrogen is 
deemed to prevent further growth (Bosland, 2005).  However, various studies have 
suggested the estrogens in prostate cancer treatment may lead to breast cancer in males.  
Schlappak et al. (1986) in a review of 19 cases of breast cancer in males found two 
patients (~10%) to have been taking estrogen for 12-years for their treatment of prostate 
cancer.   
Obesity. Peripheral conversion of testosterone into estrogen by adipocytes has been 
hypothesized as the source of increased estrogen seen in obese males (Lee et al., 2013).  
Casagrande et al. (1998) conducted a case-control analysis of 75 cases of male breast 
cancers, to examine the risks associated with endocrine elements.  From all the factors 
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measured, such as family history of cancer and lab analysis of serum levels, obesity was 
the only risk factor found.  The authors stated that there was a doubling of risk for 
individuals that weighed 80 kg or more at 30-years of age, compared to those that 
weighed 60 kg or less of the same age.  Casagrande and colleagues found lower levels of 
sex hormone binding globulin (SHBG), a protein that binds and sequesters estrogen, in 
obese men, which they believed suggested higher levels of free estrogen was circulating 
in obese men.  Many studies following Casagrande et al.’s seemed to echo the same 
results: obesity is a risk factor for male breast cancer (Hsing et al., 1998; Ewertz et al., 
2001; Johnson et al., 2002; Brinton et al., 2008), probably because high levels of estrogen 
are found in obese men. 
MtF 
A recent literature review done by Joint et al. (2018) uncovered a total of 20 
breast cancers in MtF individuals, found in three cohort studies and 12 individual case 
reports.  Cohort studies were done in a retrospective manner, with two cases found in a 
cohort study of 2,307 MtF individuals (Gooren et al, 2013), resulting in an incidence rate 
of 4.1 per 100,000 person-years, which was stated as being close to the expected rate in 
cismen (1 per 100,000py) but lower than the rate expected in ciswomen (130 per 
100,000py; Gooren et al, 2013).  Two more cases found in another cohort study that 
consisted of 5,135 transwomen (Brown et al, 2015), with an incidence rate of 0.03 per 
100,000 person-years, and stated to not be significant in regards to expected rates in 
ciswomen (Brown et al, 2015).  The remainder of the 20 breast cancers found, were from 
12 case reports that resulted in 16 cases of breast cancers (Cormen et al., 2016; Gooren et 
al., 2015; Sattari et al., 2015; Teoh et al., 2015; Gondusky et al., 2015; Maglione et al., 
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2014; Pattison et al., 2013; Dhand & Dhaliwal, 2010; Grabellus et al., 2005; Ganly, 1995; 
Pritchard et al., 1988; Symmers, 1968).  In summary, from the case reports and cohort 
studies we can deduce a total of 7,453 transsexual persons were included, and 20 were 
found to have breast cancer.   
All cases were of epithelial breast cancer, half of them consisting of invasive 
carcinomas (50%); adenocarcinomas (15%); ductal carcinomas (10%); unspecified breast 
carcinomas (10%); ductal carcinomas in situ (5%) and secretory carcinomas.  According 
to Joint and colleagues (2018) in the MtF cohort there were 17 cases with ER positivity 
(52.9%), 15 cases with PR positivity (40%) and three cases that were receptor negative.  
BRCA testing was done on five cases, with one testing positive for the BRCA2 mutation.  
From the 20 cases of breast cancer, 19 patients were on HT before their diagnosis, with 
the duration ranging from 6 to 37-years.  There were eight cases that described the effect 
of breast cancer diagnosis in their continuation of HT, with five deciding to fully stop HT 
and two deciding to continue, while one was recommended to stop but further details 
were not found.  Sixteen of the 20 cases mentioned their discussion of treatment path, 
however one died before beginning their treatment, and another discharged herself before 
starting treatment, while the rest (14) decided to do treatment.   
Stromal Density 
One of the most important and strongest risks for breast malignancies in 
ciswomen is an increase in breast density (Byrne et al., 1987).  Density in the breast 
involves the microenvironment comprised of the stroma and fibroglandular tissue, which 
aid in the growth and maintenance of the epithelia (Modern surgical pathology CH 19).  
McCormack and Silva (2006) conducted a meta-analysis on mammogram data from 42 
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reports, with a total of over 14,000 cases of breast cancer and 226,000 non-cancerous 
mammogram (controls).  The authors set to examine the possible risk associated with 
breast density and breast cancer in patterns of mammogram studies.  Upon finishing their 
examination, they concluded that strong linear trends appeared with density, thus, 
defining increase in density of breast tissue as a risk factor for breast cancer.  Similar 
studies arrived at the same conclusions, that increased density is indicative of risk for 
breast cancer (Dontchos et al, 2015; Ursin et al., 2005; Clemons & Goss, 2001; Li et al., 
2005; Brinton et al, 1991; Byrne et al., 1987), but more specifically, Boyd et al. (2002) 
stated that denser breasts in women are shown to have more than a 4-fold risk of breast 
cancer.   
Research and evidence of breast cancer risks in ciswomen with denser breasts 
continues to increase and is of the main concerns for clinicians when diagnosing, aside 
from sex and age.  In regards to transwomen, a widely used study by current researchers, 
Weyers et al. (2010), stated that approximately 60% of the transwomen in their study had 
“very dense” breasts.  Their study included 50 Dutch transwomen, where density in those 
individuals was due to the presence of more than 25% dense tissue seen in 
mammography.  According to Phillips et al (2014) transwomen develop a wide variety of 
breast tissue, with more individuals than not demonstrating higher density.  Their study 
on mammography images of MtF individuals, recommended that imagers (radiologists) 
be cognizant of the impact of long-term use of estrogen on breast density in trasnwomen, 
because it is not the same breast tissue seen in males with gynecomastia, which is often 
used as a reference due to higher levels of estrogen seen.    
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 Additionally, breast density has been shown to prevent the ability to detect 
malignancies in mammogram images (Kerlikowske et al., 1996).   In terms of 
mammogram imaging, density is the proportion of white (in appearance) sections 
(connective tissue), relative to the dark regions (fatty tissue).  Sensitivity of mammogram 
screening is reduced in the presence of increased density, which causes inaccurate 
readings of mammograms and possible misdiagnosis of tumors (Corney et al., 2003).  For 
women whose breasts is “fatty” (appeared dark in imaging) mammogram sensitivity is 
approximately 87% with specificity of 96.6% (Corney et al., 2003).  However, in women 
with very dense breasts, sensitivity is approximately 62.9% and specificity 89.6% 
(Corney et al., 2003).  Thus, denser breasts are shown to increase the risk of breast 
cancer, and also, decrease mammogram sensitivity, which prevent accurate detection of 
breast malignancies, which can lead to poorer outcomes. 
Other Potentially Contributing Risk Factors 
Health disparities in ciswomen. Most disparities that contribute towards risks of breast 
cancer focus on racial disparities, which are predominantly seen in black women (Bigby 
et al., 2004), but have neglected to investigate other racial groups and variables.  The 
American Cancer Society  (2019) has shown that in the comparisons between men and 
women, women of color are in fact at a higher risk for breast cancer when matched to 
their male counter parts.  For instance, white men are 100 times less likely to develop 
breast cancer compared to white women, and black men are also less likely to develop 
breast cancer when compared to the risk seen in black women.  When comparing the 
risks between black women and white women, mortality rates of breast cancer in black 
women are higher; these are attributed to lack of adequate screening and diagnosis 
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(Bigby et al., 2005).  Lower rates of screening were seen in black women (Clark et al., 
1999), which led to efforts in increasing mammography screening, that resulted in similar 
rates of mammograms in black women compared to non-black (Willet et al., 2004).  
However, data demonstrated a 25-30% (Schneider & Epstein, 2002) decrease in self-
reported (asking the patient to rate themselves during medical questionnaires and/or 
clinical interviews) screening within the same population, which coincided with studies 
that non-white women tend not to follow-up after abnormal results in mammograms 
(Bigby et al., 2004).  The combination of all these studies demonstrates that barriers to 
access to care and lack of preventive and survival education can increase negative 
outcomes in populations experiencing these health disparities.   
 A large amount of evidence implies that cancer disparities in black women are 
due to lack of screening, which results in later stages of cancer at diagnosis (Daly & 
Olepade, 2015), and reduced access to care (Newman & Kaljee, 2017).  A meta-analysis 
of geographical mortality rates of breast cancer in the U.S showed that in only four 
counties were the outcomes for black women optimal (Rust et al., 2016).  The authors 
researched 762 U.S counties to examine the consistent mortality rates seen for black 
women, because since 1989 mortality rates have declined for all groups except black 
women.  They examined data from counties during 1989-2010 where more than half 
(54%) demonstrated consistent and unchanging disparities.  More specifically, 
approximately, 1 in 4 (24%) had a pattern of worsening disparities in black versus whites.  
This study coincided with literature on mortality rates and trends that suggest a 
contribution of social and structural factors for breast cancer risks seen in geographical 
variations (Grubbs et al., 2013).  Changes to make health care more equitable in 
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Massachusetts, Delaware and Connecticut reflected positive outcomes in their mortality 
rates and contributed to the elimination of breast cancer disparities (Sighoko et al., 2013; 
Hunt & Hurlbert, 2013; Van Deer et al., 2013). Thus, lack of screening in disadvantage 
populations result in worst cancer outcomes that are due, in large part, to health 
disparities. 
Health disparities in MtF. Transgender patients face numerous obstacles during their 
transition journey, including lower rates of healthcare coverage, reduced financial means 
and negative social stigma from their health practitioners.  Current health insurance plans 
typically deny coverage for medically necessary procedures, such as prescriptions for sex 
steroids for HT, needed for the transition of a transgender patient (Padula et al., 
2015).  Therefore, financial issues are the most common barriers to health-care access for 
transgender patients (Bucket et al., 2018).  Financial barriers to health care have been 
demonstrated to in a recent study by Fenn et al., (2014) to be the strongest independent 
predictor of poor quality of life in survivors of cancer, which in this case, would reiterate 
the weight of the financial burden in MtF populations and the risks of poorer outcomes 
when cancer does strike.  
Barriers to health insurance coverage place a financial hardship on transgender 
patients (Padula et al., 2015), which often pushes patients to resort to sources of treatment 
outside of the medical community for HT (Bucket et al., 2018).  The use of non-
prescribed HT is common and an ongoing concern, with patients arriving to the 
emergency department from complications due to needle sharing, pulmonary embolism, 
deep vein thrombosis (DVT) and hyperkalemia (Kaiser et al., 2016). A recent study n San 
Francisco by Haan et al. (2015) analyzed data from 314 transwomen and found that 
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approximately 49% of those on HT were using non-prescribed dosages (68.7% reported 
being on HT) and only 41% were on it consistently, which can pose a health hazard 
around breast cancer, if dosage is unknown. 
 Even if a patient is able to afford medical care, transgender patients face common 
issues in the hands of health care professionals (Belluardo-Crosby et al., 2012).  
Education and training for clinicians on providing quality care for transgender patients is 
profoundly absent (Belluardo-Crosby et al., 2012).  Transgender patients have reported 
being seen by medical providers who did not know how to best provide for them; the 
providers were unaware of transition-related care or the spectrum of transgender patients 
(Bucket et al., 2018).  Transgender patients also consistently report experiencing bias and 
stigma from clinicians, in the form of the inappropriate medical records, wrong name 
and/or pronoun usage, invasive questions and the perpetuation of beliefs in only two 
genders (Padula et al., 2015).  The combination of the lack of education and inexperience 
of the medical community, conflated with the bias and stigmatization contribute to health 
disparities and barriers that transgender persons face during their transition (Padula et al., 
2015). 
HT in MtF. Estrogen intake in an MtF patient is the more common HT used (Moore et 
al., 2003).  The intake of exogenous estrogen by an MtF patient reduces androgen 
secretion, through the suppression of pituitary gland secretion of gonadotropin hormones 
(Dittrich et al., 2005).  However, there is a widely held belie that the desired androgen 
suppression is typically not achieved by estrogen alone, so anti-androgens are also 
prescribed.   
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A review on the guidelines and HT types and dosages by Unger (2016) showed 
that the typical estrogen intake by an MtF patient was two to three times higher than 
dosages typically used in HRT for postmenopausal women.  Coinciding with prior 
notions that HT for MtF individuals was modeled loosely after HRT for postmenopausal 
women (Moore et al., 2003).  Unger’s review showed that the most common form of 
estrogen in HT was in the form of a pill (estradiol: 2-4 mg daily) and/or transdermal 
patch (estradiolvalerate: 5-50 mg every two weeks).  Compared to Ratner and Ofri (2001) 
review of common types and dosages of estrogen in HRT of postmenopausal women: 
ethinyl estradiol (0.02 mg PO daily) and transdermal path (0.05 mg, 1 patch twice a 
week), the difference is uncanny.  The use of ethinyl estradiol has been limited and 
cautioned for usage in MtF individuals because of studies demonstrating the increase of 
risk thromboembolism and even cardiovascular death (Asscheman et al., 2011).   As far 
as anti-androgens, spironolactone appeared to be the most common form of anti-androgen 
prescribed in Unger’s review.   
A recent study by Cuhna et al. (2018) reported that estrogen alone sufficed to 
lower testosterone levels in MtF patients.  The authors examined serum levels of 51 
transwomen after being placed on two types of estrogen regimen.  Forty-one patients 
were given 0.625 mg of conjugated equine estrogen and the remaining 10 were placed on 
1.25 mg.  Cyproterone acetate (anti-androgen) was also given to 43 of the patients; 50 mg 
to 42 and one was given 100 mg.  Authors decided on cyproterone acetate instead of 
spironolactone citing its implications in a synergistic estrogen effect towards physical 
changes (Prior et al., 1989).  The authors concluded that low dosages of estrogen therapy 
alone reduced testosterone levels from 731.5 ng/dL to 18ng/dL, and the addition of 
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cyproterone reduced the levels from 750 ng/dL to 21 ng/dL (no statistical difference).  
Thus, MtF individuals do not need to be exposed to high dosages of estrogen, which can 
cause a variety of detrimental and unforeseen consequence in order to achieve feminizing 
hormone levels equal to that in ciswomen.  More importantly, patients in their cohort 
study developed breast in accordance with stage four and five of the Tanner Stages, 
“Areola elevated above contour breast, forming ‘double scoop’ appearance,” Areolar 
mound recedes back into single breast contour with areolar hyperpigmentation, papillae 
development and nipple protrusion,” respectively.  
According to Heijer et al. (2017) most guidelines leave the dosage of transitioning 
steroids in the hands of practitioners.  Under the influence of blood samples, clinicians 
are to monitor side effects of HT while achieving the goal of feminization.  Heijer et al. 
states that the fullest effect of HT is typically seen in the first 2-5-years of use, comparing 
it to the typical pattern seen during female puberty.  After that time frame, HT is to be 
used for maintenance of the achieved feminization.  The authors mention that although 
feminization is the goal, side effects, such as hypogonadism, from HT are to be closely 
monitored to ensure that the overall well being of the patient is precedence. 
Discussion 
 Epithelial breast cancers in ciswomen (12%) are an established topic of concern 
and research, but as of now, current literature does not signal the same for 
transwomen.  Furthermore, in ciswomen stromal tumors make up less than 1% of tumors.  
Case reports on MtF patients with stromal lesions depict a different notion for this 
population. Within the last two years, three cases were reported showing the presence of 
rare stromal lesions.  All three tumors, Myofibroblastoma (MFB), Pseduoangiomatous 
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stromal hyperplasia (PASH) and Phyllodes Tumor (PT) have been described as rare 
entities to occur in both male and females, with stromal proliferation and possible 
etiologies linked to aberrant hormonal levels, more specifically estrogen.  Ciswomen with 
stromal tumors comprise less than 1% of breast cancers.  Here I have identified three 
cases of MtF individuals with stromal tumors, and current literature depicts the number of 
epithelial tumors in MtF women as 20 reported cases.  Therefore, the ratio in transwomen 
seems very different to those in ciswomen. 
 Considering the intake of sex steroids in these three stromal lesion cases the 
questions arises, is there reason to expect that the MtF rate of stromal malignancies will 
be significantly greater than that seen in ciswomen?  From the small sample size 
available through current literature, there are only 20 cases of epithelial breast cancer in 
MtF individuals reported globally, in comparison to 12% lifetime incidence rate of 
ciswomen.  However, when taking these three stromal lesion cases in comparison to 
those 20 of epithelial origins, the ratio (3:20) produces a 15% value of stromal 
incidences, which is more than 15x greater than that seen in ciswomen (less than 
1%).  This calculation is dependent on the limited published studies, which are composed 
of a very small sample size.  However, this can be something that the medical community 
could try to track better to determine its validity.  In the meantime, research on breast 
cancer in ciswomen could give insight to the possible contributions of estrogen in these 
developments. 
 The majority of breast cancers found in ciswomen are epithelial (99%), ER-
positive (80%) and of those, 65% are PR-positive, thus research on hormone receptors is 
key to better grasp the pathological development of breasts.  Hormone receptors are 
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found distributed among the breast tissue and mediate proliferation and differentiation 
upon activation from sex steroids (estrogen and progesterone).  Considering that MtF 
patients are essentially prompted to undergo female puberty upon the introduction of HT, 
the absence of higher numbers in epithelial cancers is confounding.  Estrogen in 
ciswomen has been labeled as the possible trigger for neoplastic growth, why aren’t MtF 
patients’ demonstrating epithelial breast cancer incidence rates equal to those found in 
ciswomen?  Two obvious possibilities include, one, the health disparities and aversion to 
care (or lack of adequate care) of the trans community are disguising a larger problem.  
Secondly, the duration of estrogen exposure for most transwomen today is still short 
compared to a postmenopausal ciswoman, who doesn’t reach peak breast cancer age risk 
until she has had 35 years of estrogen exposure and then lived another 20 years.  Very 
few transwomen have been using HT for 35 years, and fewer began their transition 55 
years ago, therefore, individually or a combination of both could contribute to low rates 
seen in data today.  Why do I think rates will go up with additional data? 
 I think there are several reasons to expect the incidence of breast cancer in the 
MTF community to rise. First, HT is more widely accepted as a treatment for MtF and 
gender dysphoria, therefore, it is reasonable to expect that more transgender persons will 
begin receiving appropriate HT beginning as early as puberty (Unger, 2016).  This 
increase in lifetime estrogen is expected to increase incidence because women in general 
have higher incidences than men (100x), and even the short term intake of exogenous 
estrogen in HRT by postmenopausal has been stated to cause a 2.3% increase risk in 
breast cancer development (The Hormonal Group, 1997).  Secondly, most MtF HT is 2-
3x higher in concentration than HRT for postmenopausal women, again, increasing 
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potential risk. Third, denser breast tissue has been established to increase the risk of 
breast cancer by a 4-6-fold.  Both MtF and HRT users have been noted to have denser 
breast tissue, 60% and 75% respectively.  Fourth, is medical access for MtF improving 
(for example, are some insurance plans covering treatment?) If so, this will likely 
increase the number of trans women with access to hormones, increasing the population. 
Fifth, although 
MtF patients are typically compared to ciswomen for control purposes, it is 
important to examine the possible relationships in males with increased estrogen.  A 50-
fold increase of breast cancer risk has been noted for individuals Klinefelter Syndrome 
(KS); the risks are attributed to the increase levels of estrogen in the estrogen to 
testosterone ratio.  KS individuals have higher levels of estrogen and lower testosterone 
due to the extra X-chromosome and have excess peripheral conversion of available 
testosterone into estrogen. MTF women have a similar profile due to taking estrogen and 
androgen blockers. Sixth, another estrogen-driven disorder in males is gynecomastia, 
where coincidentally, PASH tumors are closely associated to develop on lie of 
gynecomastia in males (PASH tumor is one of the stromal lesions found in the case 
reports of MtF stromal malignancies).  Gynecomastia is due to an increase of estrogen in 
males. Although these patients have not been identified to be at risk for breast cancer, 
males with gynecomastia are at risk to develop testicular cancer, which develops due to 
increase estrogen levels, indicating that estrogen-sensitive tumors can arise in XY 
individuals exposed to estrogens.  
In regards to epithelial breast cancer rates in MtF, my assessment is compromised 
due to the small sample size that is available in the literature.  Since the sample size of 
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transgender persons is small, it could be that the rate for epithelial breast cancer is too 
low or too high.  However, right now, with all the other information I found, I believe 
that number is too low, because the rate of breast cancer in MtF is only 4-fold greater 
than cismen, which are not under the influence of exogenous estrogen.  I think that the 
population of transwomen will expand, because I believe there are more people that 
identify as transgender today, but, either do not have access to care or do not feel safe and 
secure to seek care.  When financial barriers are removed and more MtF individuals can 
afford HT; and as our society, as a whole, becomes more accepting and inclusive towards 
transgender individuals; and as more medical providers are better trained to provide 
adequate care, the transgender population will expand.  As the population of transgender 
persons grows, trasnwomen will be on HT longer and we will have more data to 
accurately depict the correct rates of breast cancer in this population.  These observations 
reflect a correlation between estrogen and breast cancer risks, but all of the trends point in 
the same direction.  Hopefully this observation will encourage possible research 
approaches in the future. 
 In the stromal cases found in MtF patients again we find a small sample size that 
could affect the actual rates.  There are reason to expect this rate is higher, for instance, 
there is a high percentage of stromal density found in transwomen and when compared to 
the statistics of breast cancer risks in ciswomen, denser breasts are considered to have a 
4-6-fold increase risks of breast cancer (McTiernan et al., 2005).  Another reason can be 
due to the small amount of overall information we have on stromal malignancies in the 
general population that can contribute to a decrease in awareness in medical providers.  If 
little is known about stromal lesions and medical providers rarely see these lesions in 
  42
cismen or ciswomen, when compounded with the lack of education in medical providers 
for the care of MtF persons, this attributes to a decrease in findings and reports of stromal 
lesions in MtF persons.  Amounts and types of estrogen for HT in MtF patients are not 
under guidelines or strict monitoring by medical institutions, which could also contribute 
to higher rates in the future.  The rate of stromal lesions in MtF could also be lower, 
because stromal lesions are a rare entity in ciswomen, the population with most exposure 
to estrogen in their lifetime, but that is the point of a small sample size.  The small sample 
size of transwomen with stromal lesions could be a sampling error, that could be an error 
on the high end of the spectrum or the low end, but the only way to decide is to have 
bigger numbers.  Along with the financial obstacles, lack of education in clinicians and 
stigmatization from providers, the health disparities that this population face, further 
conflate this topic.  
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